Fulvestrant
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Locally Advanced or
Conditions
Locally Advanced or, Metastatic Breast Cancer
Trial Timeline
May 29, 2015 → Sep 16, 2020
NCT ID
NCT02447328About Fulvestrant
Fulvestrant is a approved stage product being developed by AstraZeneca for Locally Advanced or. The current trial status is completed. This product is registered under clinical trial identifier NCT02447328. Target conditions include Locally Advanced or, Metastatic Breast Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Locally Advanced or were approved
Approved (4) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02447328 | Approved | Completed |
| NCT02000193 | Phase 2 | UNKNOWN |
| NCT01186796 | Phase 1 | Completed |
| NCT00927511 | Phase 2 | UNKNOWN |
| NCT00660803 | Pre-clinical | Completed |
| NCT00476645 | Phase 2 | Completed |
| NCT00313170 | Phase 2 | Completed |
| NCT00278915 | Phase 2 | Completed |
| NCT00099437 | Phase 3 | Active |
| NCT00093002 | Phase 2 | Completed |
| NCT00328120 | Phase 1 | Completed |
| NCT00334295 | Phase 2 | Completed |
| NCT00272740 | Phase 2 | Completed |
Competing Products
20 competing products in Locally Advanced or